1. |
Savage KJ, Chhanabhai M, Gascoyne RD, et al. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO lassification[J]. Ann Oncol, 2004, 15(10):1467-1475.
|
2. |
Jaffe ES. Harris NL, Stein H. World Health Organization classification of tumours:pathology and genetics of tumours of the haemelopoietic and lymphoid tissues[M]. Lyon:IARC Press, 2001.
|
3. |
Savage KJ, Ferreri AJ, Zinzani PL, et al. Peripheral T-cell lymphoma-not otherwise specified[J]. Crit Rev Oncol Hematol, 2011, 79(3):321-329.
|
4. |
Delmer A, Mounier N, Gaulard P, et al. Intensified induction therapy with etoposide (VP16) and high-dose cytarabine (Ara-C) in patients aged less than 60 years with peripheral T cell/NK-cell lymphoma:preliminary results of the GELA phase Ⅱ study LNH98T7[J]. J Clin Oncol, 2003, 22(Suppl):591.
|
5. |
Schmitz N, Trümper L, Ziepert M, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma:an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group[J]. Blood, 2010, 116(18):3418-3425.
|
6. |
Gisselbrecht C, Lepage E, Molina T, et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma[J]. J Clin Oncol, 2002, 20(10):2472-2479.
|
7. |
Rodríguez J, Caballero MD, Gutiérrez A, et al. High dose chemotherapy and atuologous stem cell transplantation in peripheral T-cell lymphoma:the GEL-TAMO experience[J]. Ann Oncol, 2003, 14(12):1768-1775.
|
8. |
Song KW, Mollee P, Keating A, et al. Autologous stem cell transplant for relapsed and refractory peripheral T-cell lymphoma:variable outcome according to pathological subtype[J]. Br J Haematol, 2003, 120(6):978-985.
|
9. |
Rodríguez J, Conde E, Gutiérrez A, et al. The adjusted International Prognostic Index and beta-2-microglubulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma[J]. Haematolngica, 2007, 92(8):1067-1074.
|
10. |
安刚, 齐元军, 邱录贵. 外周T细胞淋巴瘤的治疗进展[J]. 中华血液学杂志, 2008, 29(10):719-720.
|
11. |
Corradini P, Dodero A, Zallio F, et al. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopeietic cells[J]. J Clin One01, 2004, 22(11):2172-2176.
|
12. |
Majhail NS. Burns U. Hematopoietic stem cell transplantation in the treatment of pephend T-cell lymphomas[J]. Curr Hematol Rep, 2005, 4(4):252-259.
|
13. |
Zinzani PL, Venturini F, Stefoni V, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients:evaluation of the long-term outcome[J]. Ann Oncol, 2010, 21(4):860-863.
|
14. |
Arkenau HT, Chong G, Cunningham D, et al. Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma:the Royal Marsden Hospital experience[J]. Haematologica, 2007, 92(2):271-272.
|
15. |
Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas[J]. Blood, 2004, 103(8):2920-2924.
|
16. |
Kluin-Nelemans HC, Coenen JL, Boers JE, et al. EBV-positive immunodefieiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell Iymphoma[J]. Blood, 2008, 112(4):1039-1041.
|
17. |
D'Amore F, Radford J, Relander T, et al. PhaseⅡ trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma[J]. Br J Haematol, 2010, 150(5):565-573.
|
18. |
O'Connor OA, Hamlin PA, Gerecitano J, et al. Pralatrexate (PDX) produces durable complete remissions in patients with chemotherapy resistant precursor and peripheral T-cell lymphoma. Results of the MSKCC PhaseⅠ/Ⅱexperience[J]. Blood, 2006, 108(11):122A-123A.
|
19. |
Mould DR, Sweeney K, Dufull SB, et al. Apopulation pharmacokinenetic and pharmacodynamic evaluation of pralatrexate in patients with relapsed or refractory non-Hodhkin's or Hodgkin's lymphoma[J]. Clin Pharmacol Ther, 2009, 86(2):190-196.
|
20. |
Dang NH, Pro B, Hagemeister FB, et al. PhaseⅡ trail of denileukin diflitox for relapsed/refractory T-cell non-Hodgkin lymphoma[J]. Br J Haematol, 2007, 136(3):439-447.
|
21. |
Venugopal B, Evans TR. Developing histone deacetylase inhibitors as anti-cancer therapeutics[J]. Curr Med Chem, 2011, 18(11):1658-1671.
|
22. |
Cotto M, Cabanillas F, Tirado M, et al. Epigenetic therapy of lymphoma using histone deacetylase inhibitors[J]. Clin Transl Oncol, 2010, 12(6):401-409.
|
23. |
Olsen EA, Kim YH, Kuzel TM, et al. PhaseⅠb multicenter trail of vorinostat in patients with persistent, progressive,or treatment refractory cutaneous T-cell Lymphoma[J]. J Clin Oncol, 2007, 25(21):3109-3115.
|
24. |
Bates SE, Zhan Z, Steadman K, et al. Laboratory correlates for a phaseⅠ trail of romidepsin in cutaneous and peripaheral T-cell lymphoma[J]. Br J Haematol, 2010, 148(2):256-267.
|
25. |
Piekarz RL, Frye R, Turner M, et al. Responses and molecular markers in patients with peripheral T-cell lymphorna treated on a phaseⅠ trial of depsipeptide[J]. J Clin Oncol, 2005, 23(16S):3061.
|
26. |
Zinzani PL, Musuraca G, Tani M, et al. PhaseⅠ trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma[J]. J Clin Oncol, 2007, 25(27):4293-4297.
|
27. |
Yamamoto K, Utsunomiya A, Tobinai K, et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma[J]. J Clin Oncol, 2010, 28(9):1591-1598.
|
28. |
O'Connor OA, Masszi T, Savage KJ, et al. Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL):results from the BELIEF trial[J]. J Clin Oncol, 2013, 31(18S):8507.
|
29. |
O'Brien SM, axton Df CM. PhaseⅠ study of obatoclax mesylate (GXl5-070) a small mo1ecule pan-bcl-2 family antagonist in patients with advanced chronic lymphocytic leukemia[J]. Blood, 2009, 113(2):299-305.
|
30. |
朱军, 丁宁. 从机制阐述淋巴瘤治疗药进展[N]. 医师报, 2013-01-05(5).
|
31. |
Bruns I, Fox F, Reinecke P, et al. Complete remission in a patient with relapsed angioimmunoblastic T-cell lymphoma following treatment with bevacizumab[J]. Leukemia, 2005, 19(11):1993-1995.
|
32. |
Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma[J]. Blood, 2011, 117(25):6756-6767.
|